Drawing for BEIGENE

USPTO serial 90647330

BEIGENE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
KETCHUM, BRENDAN J
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BEIGENE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kristen S. Ruisi

Kristen S. Ruisi VENABLE LLP1270 AVENUE OF THE AMERICAS, 24TH FL.ROCKEFELLER CENTERNEW YORK, NY 10020

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseasesACTIVE—
040Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseasesACTIVE—
042Research and development of new products for others; technological research in the field of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical research; conducting clinical trials for others for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological research; quality control for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; electronic data storage; material testing; cloud computing featuring software for use in database management, word processing, spreadsheet management, tracking; packaging designACTIVE—
044Telemedicine services; health care; convalescent home services; beauty salon services; physical therapy services; gardening; veterinary services; health counseling; pharmacy advice, namely, pharmaceutical advice; rental of sanitary installationsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jan 17, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 16, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 7, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 5, 2022EX1GSOU EXTENSION 1 GRANTED—
Apr 5, 2022EXT1SOU EXTENSION 1 FILED—
Apr 5, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 14, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 19, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 19, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 29, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 13, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 8, 2021DOCKASSIGNED TO EXAMINER—
Jul 23, 2021MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jul 22, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 19, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance